ReviewCancers2016
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer.
Review in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 75 citations in OpenAlex.
- Article
- A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.Breast cancer research : BCR · 2024Article
- Androgen receptor expression and clinical characteristics in breast cancer.World journal of surgical oncology · 2024Article
- Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans.Biomedicines · 2024Article
- HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.International journal of oncology · 2024Article
- Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.International journal of molecular sciences · 2024Review
- [Diagnostics (Basel, Switzerland) · 2023Review
- Nuclear Receptor Imaging In Vivo-Clinical and Research Advances.Journal of the Endocrine Society · 2023Review
- Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?Breast cancer (Dove Medical Press) · 2023Article
- Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.Biologics : targets & therapy · 2023Review
- Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer.Biomedicines · 2022Review
- Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer.Breast cancer : basic and clinical research · 2022Review
- Imaging Androgen Receptors in Breast Cancer withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- High claudin-4 antigen expression in triple-negative breast cancer by the immunohistochemistry method.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Article
- Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Identification of the anti-breast cancer targets of triterpenoids in Liquidambaris Fructus and the hints for its traditional applications.BMC complementary medicine and therapies · 2020Article
- AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-Mediated redox homeostasis.Redox biology · 2020Article
- Article
- Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.Sexual medicine reviews · 2019Review
- Development of selective androgen receptor modulators (SARMs).Molecular and cellular endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular and histopathological profiling have classified breast cancer into multiple sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments. The high expression of AR in breast cancer and recent discovery and development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer. This review provides a detailed account of AR's therapeutic role in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.